Diverging Trends in the Incidence of Reflux-related and Helicobacter Pylori-related Gastric Cardia Cancer

Overview

Journal J Clin Gastroenterol

Specialty Gastroenterology

Date 2012 Aug 24

PMID 22914345

Citations 17

Authors

Julian A Abrams

Lou Gonsalves

Alfred I Neugut

Affiliations

Soon will be listed here.

Abstract

Goals: To describe historical incidence trends of 2 subtypes of gastric cardia cancer.

Background: The incidence of gastric cardia cancer has increased in western countries. Prior studies have treated cardia cancer as a single entity, but recent data suggest that there are 2 distinct subtypes: reflux-related and Helicobacter pylori-related.

Study: We conducted a population-based study using Connecticut Tumor Registry data from 1955 to 2007. Age-adjusted incidence rates (per 100,000 person-years) were calculated for gastric cancer, as a whole and by anatomic subsite, and for esophageal adenocarcinoma. Cardia and noncardia cancer incidence rates were further adjusted to account for cases with unspecified subsite. Mathematical formulas were derived to calculate incidence rates for reflux-related and H. pylori-related cardia cancer.

Results: The adjusted incidence of cardia cancer was 4.0 per 100,000 in 1955 to 1959, decreased to 2.4 per 100,000 in 1965 to 1969 before increasing to 3.4 per 100,000 by 2003 to 2007. The incidence of H. pylori-related cardia cancer decreased from 3.7 to 1.0 per 100,000 over the study period, whereas reflux-related cardia cancer increased progressively from 0.3 to 2.4 per 100,000. The curves for reflux-related cardia cancer and esophageal adenocarcinoma closely mirrored each other, and their combined incidence increased from 0.5 per 100,000 in 1955 to 1959 to 5.6 per 100,000 in 2003 to 2007.

Conclusions: The incidence of reflux-related cardia cancer has steadily increased, whereas H. pylori-related cardia cancer has declined progressively since the mid-20th century. Trends in reflux-related cardia cancer and esophageal adenocarcinoma incidence are very similar, suggesting that these 2 cancers share a similar etiology and pathophysiological process.

Citing Articles

Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.

Morgos D, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S Int J Mol Sci. 2024; 25(3).

PMID: 38339127 PMC: 10856016. DOI: 10.3390/ijms25031848.

Risk factors associated with gastric malignancy during chronic Infection.

Seeger A, Ringling M, Zohair H, Blanke S Med Res Arch. 2023; 8(3).

PMID: 37655156 PMC: 10470974. DOI: 10.18103/mra.v8i3.2068.

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab.

Schade S, Koenig U, Mekolli A, Gaedcke J, Neesse A, Reinecke J Case Rep Gastroenterol. 2022; 16(1):80-88.

PMID: 35350679 PMC: 8921895. DOI: 10.1159/000520057.

Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.

Potzsch M, Berg E, Hummel M, Stein U, von Winterfeld M, Johrens K Oncoimmunology. 2020; 9(1):1824632.

PMID: 33101772 PMC: 7553533. DOI: 10.1080/2162402X.2020.1824632.

The role of the gastric bacterial microbiome in gastric cancer: and beyond.

Schulz C, Schutte K, Mayerle J, Malfertheiner P Therap Adv Gastroenterol. 2020; 12:1756284819894062.

PMID: 31897087 PMC: 6920592. DOI: 10.1177/1756284819894062.

References

Kamangar F, Dawsey S, Blaser M, Perez-Perez G, Pietinen P, Newschaffer C . Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006; 98(20):1445-52. DOI: 10.1093/jnci/djj393. View

Banatvala N, Mayo K, Megraud F, Jennings R, Deeks J, Feldman R . The cohort effect and Helicobacter pylori. J Infect Dis. 1993; 168(1):219-21. DOI: 10.1093/infdis/168.1.219. View

Derakhshan M, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A . Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut. 2007; 57(3):298-305. DOI: 10.1136/gut.2007.137364. View

Botterweck A, Schouten L, Volovics A, Dorant E, van den Brandt P . Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000; 29(4):645-54. DOI: 10.1093/ije/29.4.645. View

Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, Blaser M . Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst. 2001; 93(3):226-33. DOI: 10.1093/jnci/93.3.226. View

Rautelin H, Koskela P, Sarna S, Pukkala E, Aromaa A, Knekt P . Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer. Epidemiol Infect. 2001; 126(1):37-42. PMC: 2869672. View

. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49(3):347-53. PMC: 1728434. DOI: 10.1136/gut.49.3.347. View

Lagergren J, Bergstrom R, Lindgren A, Nyren O . Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340(11):825-31. DOI: 10.1056/NEJM199903183401101. View

Kamangar F, Qiao Y, Blaser M, Sun X, Katki H, Fan J . Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer. 2006; 96(1):172-6. PMC: 2360212. DOI: 10.1038/sj.bjc.6603517. View

10.

Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H . Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control. 2010; 22(3):375-87. DOI: 10.1007/s10552-010-9707-2. View

11.

Fitzgerald R, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V . Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010; 47(7):436-44. PMC: 2991043. DOI: 10.1136/jmg.2009.074237. View

12.

Hansen S, Vollset S, Derakhshan M, Fyfe V, Melby K, Aase S . Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut. 2007; 56(7):918-25. PMC: 1994366. DOI: 10.1136/gut.2006.114504. View

13.

Abrams J, Sharaiha R, Gonsalves L, Lightdale C, Neugut A . Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev. 2010; 20(1):183-6. PMC: 3018857. DOI: 10.1158/1055-9965.EPI-10-0802. View

14.

Engel L, Chow W, Vaughan T, Gammon M, Risch H, Stanford J . Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95(18):1404-13. DOI: 10.1093/jnci/djg047. View

15.

de Jonge P, Wolters L, Steyerberg E, van Dekken H, Kusters J, Kuipers E . Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross-sectional study in a Dutch cohort. Aliment Pharmacol Ther. 2007; 26(1):31-9. DOI: 10.1111/j.1365-2036.2007.03344.x. View

16.

Kubo A, Corley D . Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15(5):872-8. DOI: 10.1158/1055-9965.EPI-05-0860. View

17.

Hackelsberger A, Gunther T, Schultze V, Labenz J, Roessner A, Malfertheiner P . Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia. Am J Gastroenterol. 1997; 92(12):2220-4. View

18.

Islami F, Kamangar F . Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2009; 1(5):329-38. PMC: 3501739. DOI: 10.1158/1940-6207.CAPR-08-0109. View

19.

Corley D, Kubo A . Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst. 2004; 96(18):1383-7. DOI: 10.1093/jnci/djh265. View

20.

Correa P, Houghton J . Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007; 133(2):659-72. DOI: 10.1053/j.gastro.2007.06.026. View